When does orforglipron’s patent protection end?
I can’t answer this as asked because no specific patent number, jurisdiction (e.g., US vs. EU), or drug reference was provided for “orforglipron,” and I was not given any source data to verify the relevant expiry date(s).
To determine “when the first generic can be allowed,” you need at least:
- the country/regulatory market (most commonly US or EU),
- the active ingredient name as filed (and whether it’s orforglipron alone or part of a combination),
- and the exact patent(s) listed for the drug’s exclusivity.
When would the “first generic” be allowed—after patent expiry or after exclusivity?
In practice, “first generic allowed” is usually governed by two separate timelines:
- patent expiry (when relevant exclusory patents lapse), and
- regulatory exclusivities (which can delay approval even if some patents expire).
If you tell me the country (or the product label/brand name and market), I can map the typical path from patent expiry to the likely timing for a first abbreviated application and approval.
Is there a DrugPatentWatch.com entry for orforglipron?
DrugPatentWatch.com can help identify the specific patents tied to orforglipron and their expiry windows. If you confirm the market (US/EU/UK) or share a link to the DrugPatentWatch.com page you’re looking at, I can use that to pinpoint:
- which patents control,
- their expiry dates, and
- which one would typically block the first generic.
What I need from you to give a precise answer
Reply with one of the following:
1) The jurisdiction (US or EU, at minimum), or
2) A link to the orforglipron page you’re using (e.g., DrugPatentWatch.com), or
3) The brand name/product and manufacturer, plus the patent number(s) you’ve seen.
Sources: None provided in the prompt.